Phase 2a Randomized Clinical Trial of Dupilumab (anti-IL-4Rα) for Alopecia Areata PatientsAlopecia AreataAtopic DermatitisDupilumabIgETh2Background Treatments for alopecia areata (AA) patients with extensive scalp hair loss are limited, and recent evidence supports a role for type 2 T-cell (Th2...
CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today that the first participant has been dosed in a Phase 2a clinical trial of its COVID-19 vaccine candidate, ...
/PRNewswire/ -- In a breakthrough for human milk science, researchers at City of Hope, Los Angeles, have dosed the first patient in a Phase 2a clinical trial...
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast c... was used for CTCs isolation and bio-characterization. HER2 status was assessed on CTCs by immunofluorescence. A case was defined as CTCs ...
Dermavant Sciences recently announced that the first patient has been dosed in its Phase 2a vitiligo clinical trial for topical cerdulatinib. Cerdulatinib
RG6501 (OpRegen ® ) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit.
("RNA") regulation to potentially inhibit the progression of ALS. NeuroSense completed a Phase 2a clinical trial which met its safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biological ma...
An earlier single-arm, Phase 2a clinical trial (COMBAT/KEYNOTE-202) and pre-clinical studies evaluating motixafortide in combination with PD-1 immunotherapies and chemotherapies in PDAC have been promising, suggesting the ability...
InflaRx N.V. recently announced the treatment of the first patient in a Phase 2a clinical trial evaluating the company’s lead product candidate, IFX-1, in
ADELAIDE, Australia, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Carina Biotech Limited (Carina), a cell therapy immuno-oncology company, today announced the dosing of the first patient in a Phase 1/2a clinical trial of its LGR5-targeted CAR-T cell...